Exact Sciences (EXAS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Core Viewpoint - Exact Sciences (EXAS) is expected to report a year-over-year increase in earnings and revenues for the quarter ended September 2025, with a consensus outlook indicating a significant earnings surprise potential [1][3][12]. Earnings Expectations - The consensus EPS estimate for Exact Sciences is $0.10 per share, reflecting a year-over-year increase of +147.6% [3]. - Revenues are projected to be $809.93 million, which is a 14.3% increase from the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has been revised 9.76% higher in the last 30 days, indicating a positive reassessment by analysts [4]. - The Most Accurate Estimate for Exact Sciences is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +56.25% [12]. Earnings Surprise Prediction - A positive Earnings ESP reading suggests a strong likelihood of an earnings beat, especially when combined with a Zacks Rank of 1 (Strong Buy) [10][12]. - Exact Sciences currently holds a Zacks Rank of 1, reinforcing the expectation of surpassing the consensus EPS estimate [12]. Historical Performance - In the last reported quarter, Exact Sciences exceeded the expected loss of $0.02 per share by reporting earnings of $0.22, resulting in a surprise of +1,200.00% [13]. - Over the past four quarters, the company has beaten consensus EPS estimates three times [14]. Industry Context - Apellis Pharmaceuticals (APLS), another player in the Zacks Medical - Biomedical and Genetics industry, is expected to report earnings of $0.83 per share, indicating a year-over-year change of +280.4% [18]. - Apellis Pharmaceuticals has an Earnings ESP of +33.59% and a Zacks Rank of 3 (Hold), suggesting a likelihood of beating the consensus EPS estimate [19][20].